2021 Year in Review: Non–Small-Cell Lung Cancer
2021 Year in Review: Non–Small-Cell Lung Cancer | December 29, 2021
Diabetes is associated with increased risk for a number of cancers, including NSCLC. Patients with hyperglycemic NSCLC treated with pembrolizumab show poorer PFS and earlier tumor progression when compared with NSCLC patients with normal blood glucose levels.
2021 Year in Review: Non–Small-Cell Lung Cancer | December 29, 2021
Finding the right balance between cancer-induced fatigue and immune-oncology–induced fatigue and doing enough exercise to improve general health and better cancer outcomes is a fundamental part of treating patients with cancer. Finding this balance for patients with NSCLC receiving immune-oncology therapy is a key element of overall care for these patients.
2021 Year in Review: Non–Small-Cell Lung Cancer | December 29, 2021
Data from the CodeBreaK 100 NSCLC subset population prompted the FDA to grant sotorasib accelerated approval for patients with KRASG12C mutation–positive NSCLC.
2021 Year in Review: Non–Small-Cell Lung Cancer | December 29, 2021
Sotorasib showed encouraging anticancer activity in phase 2 of a clinical trial of patients with heavily treated advanced NSCLC.
2021 Year in Review: Non–Small-Cell Lung Cancer | December 29, 2021
Immunotherapy and targeted therapy have resulted in improved survival rates in patients with NSCLC over the past decade.
2021 Year in Review: Non–Small-Cell Lung Cancer | December 29, 2021
Multidisciplinary tumor board members work closely to make the best clinical decisions for their patients with cancer to improve patient and institutional outcomes. Their decisions should be based on the clinical data of each patient in line with their own clinical and institutional guidelines.
